期刊
DIAGNOSTICS
卷 11, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/diagnostics11050805
关键词
theranostics; somatostatin receptor (SSTR); prostate-specific membrane antigen (PSMA); prostate cancer; neuroendocrine neoplasms (NEN); neuroendocrine tumors (NET); meningioma; norepinephrine transporter; neuroblastoma
Theranostics in nuclear oncology has achieved success by utilizing image-guided therapeutic concepts for various cancers, leading to prolonged survival and safety for patients. The use of theranostic agents continues to be an attractive treatment option in oncology, targeting established and emerging molecular markers for diagnostics and therapeutics.
Tracing its roots back to the 1940s, theranostics in nuclear oncology has proved successful mainly due to the beneficial effects of image-guided therapeutic concepts for patients afflicted with a variety of different cancers. The majority of these treatments are not only characterized by substantial prolongation of progression-free and overall survival, but are also generally safe, rendering theranostic agents as an attractive treatment option in various clinical scenarios in oncology. In this Special Issue Novel Theranostic Agents, nine original articles from around the globe provide further evidence on the use of the theranostic concept for neuroendocrine neoplasm (NEN), prostate cancer (PC), meningioma, and neuroblastoma. The investigated diagnostic and therapeutic radiotracers target not only established structures, such as somatostatin receptor, prostate-specific membrane antigen or norepinephrine transporter, but also recently emerging targets such as the C-X-C motif chemokine receptor 4. Moreover, the presented original articles also combine the concept of theranostics with in-depth read-out techniques such as radiomics or novel reconstruction algorithms on pretherapeutic scans, e.g., for outcome prediction. Even 80 years after its initial clinical introduction, theranostics in oncology continues to thrive, now more than ever.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据